Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Exelixis, Inc.
EIR
•Exelixis, Inc.•September 27, 2012

Exelixis, Inc. – FDA EIR, Sep 27, 2012

Record Details

An FDA inspection of Exelixis, Inc. was conducted from September 10 to September 27, 2012, marking the company's initial Good Clinical Practice (GCP) FDA inspection. The inspection, carried out under the Bioresearch Monitoring Compliance Program, focused on Exelixis's sponsor responsibilities for clinical study Protocol XL 184-301. The regulatory framework emphasized compliance with sponsor obligations, specifically 21 CFR 312.56(b).

The inspection revealed significant violations, primarily a failure to promptly ensure that investigators complied with study agreements, the general investigational plan, and applicable regulatory requirements. Key issues included persistent problems at Clinical Site 3908 with inadequate source documentation for adverse events, concomitant medications, and patient eligibility, which remained unaddressed for approximately one year. This site also exhibited instances of subjects receiving incorrect study drug dosing and informed consent deficiencies. Clinical Site 1315 showed recurring inadequate source documentation for a specific subject over an extended period. These observations indicated a failure in the sponsor's responsibility to properly monitor the study and ensure adherence to the protocol.

Michael M. Morrissey, PhD, President and Chief Executive Officer, acknowledged the observations and committed to submitting a written response to the FDA 483 within 15 business days to address the identified deficiencies.

Company
Exelixis, Inc.
Inspection date
September 27, 2012
Product type
drugs
Office
San Francisco District Office
People
  • Dieter Elhardt (company_representative)
  • Yifah Yaron (company_representative)
  • Michael Morrissey (recipient)
  • Aneel K. Sandhu (Government Employee)
  • Kirk Rosemark (company_representative)
View Company Profile

ID · 3c87130a-7a61-4694-829b-f54f7e1a621a

Violation Codes3
21 CFR 312.5021 CFR 312.56(b)21 CFR 312

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Exelixis, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.